Business
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
NEW YORK, March 25, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois.
About this update from Nuvation Bio Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":0,"height":0,"url":"https://media.zenfs.com/en/business-wire.com/d759a0be94a3a3b0ce43b90d458cffea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wh9cOIMX.QpmCSgBq.QITA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d759a0be94a3a3b0ce43b90d458cffea","width":null,"height":null},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jVgdVhm7qae99SdvzsMaqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d759a0be94a3a3b0ce43b90d458cffea","width":1200,"height":null}},"lazy":false},{"type":"text","content":"NEW YORK, March 25, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois.","length":425,"tagName":"p"},{"type":"text","content":"Presentation Overview:","length":22,"tagName":"p"},{"type":"text","content":"Title: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenograftsPresenter: Hitisha Patel, Ph.D., Director of Research, Nuvation BioSession Category: Experimental and Molecular TherapeuticsSession Title: Kinase and Phosphatase Inhibitors 3Date: Tuesday, April 29, 2025Session Time and Location: 2:00 – 5:00 p.m. CT / 3:00 – 6:00 p.m. ET; Poster Section 20Poster Board Number: 22Abstract Number: 5612","length":467,"tagName":"p"},{"type":"text","content":"The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation.","length":114,"tagName":"p"},{"type":"text","content":"About Taletrectinib","length":19,"tagName":"p"},{"type":"text","content":"Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I ...